Zapping spreading tumors could extend life on current cancer drugs
NCT ID NCT06101277
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests whether adding a targeted, tumor-destroying treatment (like focused radiation or heat ablation) can help people with certain gastrointestinal cancers—such as colorectal, small bowel, or pancreatic cancer—continue their current systemic therapy longer when only a few spots of cancer start to grow. About 300 adults with limited cancer progression will receive the ablation procedure alongside their ongoing treatment. The main goal is to see if this combination delays the need to switch or stop systemic therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
- What this could lead to
- If successful, this approach could help people with certain GI cancers stay on their current systemic therapy longer by controlling limited tumor growth with targeted ablation.
- What could go wrong
- This is a mid-stage trial, so results are not yet proven. Ablation procedures carry risks like bleeding or infection, and the benefit may not apply to all cancer types or stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2023
- Expected to finish
-
Sep 2039
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Must have one of the following histologically and/or biochemically confirmed cancers: 1. Cohort A: (Cohort removed in protocol version 4.0) 2. Cohort B: Small bowel 3. Cohort C: Pancreatic and ampullary, colorectal, and appendiceal 4. Cohort D: (Cohort removed in protocol version 4.0) 2. Provision of signed and dated informed consent form. 3. Stated willingness to comply with all study procedures and availability for the duration of the study. 4. Age ≥18 years at time of consent. 5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy. 6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\] 7. ≤ 5 progressing or new metastatic lesions. 8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist. Exclusion Criteria: 1. Medical comorbidities precluding locally ablative therapies. 2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies. 3. Progressing intracranial lesions.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ampullary cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of California, Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Can a blood test before pancreatic surgery predict a dangerous leak?
- Burning the edges: a new way to stop colon polyps from coming back
- New chemo cocktail targets pancreatic cancer at every stage
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- Bacteria-Based immunotherapy targets pancreatic tumors in first human test